Understanding depression, anxiety, bipolar disorder, schizophrenia, psychiatric medications, maternal mental health, and the importance of psychological preparation before pregnancy.
When preparing for pregnancy, conversations often begin with reproductive hormones, nutrition, medical history, and physical health.
But what about psychological well-being?
What happens when someone enters pregnancy with a history of depression, anxiety, bipolar disorder, or another psychiatric condition?
Can pregnancy influence the course of an existing mental health disorder?
How should prospective parents approach psychiatric medications?
And could identifying psychological concerns before conception help individuals navigate the emotional and physiological demands of pregnancy and parenthood?
These questions deserve the same seriousness as other areas of preconception healthcare.
In 2008, Frieder and colleagues published The Clinical Content of Preconception Care: Women With Psychiatric Conditions in the American Journal of Obstetrics & Gynecology.
The authors examined depression, anxiety disorders, bipolar disorder, and schizophrenia, emphasizing that pregnancy and the postpartum period may coincide with the onset, recurrence, or exacerbation of psychiatric illness.
They also addressed one of the most difficult questions in reproductive medicine: how to balance the possible risks of psychiatric medications against the risks of untreated mental illness.
Nearly two decades later, research has substantially expanded our understanding.
Professional guidelines now recognize mental health screening as an essential component of prepregnancy, prenatal, and postpartum care.
New studies have clarified the importance of maintaining psychiatric stability, identified promising psychological interventions, and introduced new treatments for postpartum depression.
However, important questions remain regarding the mechanisms linking maternal mental health with reproductive and developmental outcomes.
The central principle is that protecting mental health is not separate from preparing for pregnancy. It is an essential component of comprehensive reproductive healthcare.
1. Why Mental Health Matters Before Pregnancy
Pregnancy involves significant physiological, psychological, and social transitions.
Hormonal regulation changes.
Sleep patterns may become disrupted.
Personal responsibilities evolve.
Relationships and support systems may be tested.
For some individuals, these changes occur alongside an existing psychiatric condition.
For others, symptoms emerge for the first time during pregnancy or postpartum.
Preconception mental healthcare offers an opportunity to evaluate a person's history, identify potential vulnerabilities, and establish appropriate care before these changes occur.
Importantly, a history of psychiatric illness does not mean that someone cannot experience a healthy pregnancy or become an effective parent.
Nor does it mean pregnancy will necessarily worsen their condition.
The objective is individualized preparation rather than predicting an unfavorable outcome.
2. The Relationship Between Psychological Health and Reproductive Physiology
Psychological health interacts with several physiological systems.
These include the autonomic nervous system, hypothalamic–pituitary–adrenal axis, immune signaling, and metabolic regulation.
Stress-related responses can influence sleep, appetite, energy expenditure, and behavioral patterns.
Psychiatric conditions may also coexist with medical disorders or require medications that have metabolic effects.
However, these relationships are complex and bidirectional.
Changes in sleep or endocrine function can influence psychological symptoms.
Psychological distress can, in turn, affect sleep and other behaviors.
Importantly, these interactions should not be interpreted as evidence that depression or anxiety inevitably causes infertility, miscarriage, or adverse fetal development.
The presence of a plausible biological pathway does not establish a causal clinical relationship.
Preconception assessment should recognize physiological interactions without reducing psychiatric conditions to hormonal or inflammatory abnormalities.
3. Depression: More Than Feeling Sad
Major depressive disorder is a clinical condition characterized by persistent changes in mood, interest, motivation, cognition, and functioning.
Symptoms may include reduced pleasure, fatigue, changes in sleep or appetite, impaired concentration, feelings of worthlessness, and thoughts of death or suicide.
However, symptoms and severity vary substantially.
Depression may occur as a single episode or follow a recurrent course.
The original AJOG article emphasized that a history of depression can be relevant during pregnancy and postpartum because of the possibility of recurrence.
Contemporary clinical care continues to recognize previous depressive episodes as an important part of reproductive mental health assessment.
However, clinicians should avoid assuming that every person with a history of depression will experience another episode during pregnancy.
Risk depends on previous illness severity, recurrence patterns, current symptoms, treatment response, and other circumstances.
4. Depression, Pregnancy Outcomes, and the Problem of Causation
Research has identified associations between maternal depression and outcomes such as preterm birth or low birth weight.
However, interpreting these associations is challenging.
Depression may coexist with chronic illness, financial hardship, inadequate sleep, substance use, or difficulties accessing healthcare.
These factors can independently influence pregnancy outcomes.
Furthermore, studies may measure depressive symptoms using different instruments or define clinical depression differently.
Consequently, it can be difficult to isolate the effects of depression itself from the effects of associated circumstances.
This does not diminish the importance of treating depression.
Effective treatment can improve psychological health, functioning, and quality of life.
However, treatment should not be marketed as a guaranteed method for preventing obstetric complications.
The strongest reason to identify and treat depression is that maternal mental health matters in its own right.
5. Anxiety Disorders and Reproductive Health
Anxiety disorders involve patterns of fear, worry, or heightened apprehension that cause significant distress or impairment.
They include generalized anxiety disorder, panic disorder, social anxiety disorder, and other conditions.
Although obsessive-compulsive disorder and posttraumatic stress disorder are classified separately in modern diagnostic systems, they may be considered alongside anxiety disorders during perinatal mental health assessment.
Pregnancy can introduce new sources of uncertainty involving physical health, childbirth, parenting, and relationships.
However, having concerns about pregnancy does not automatically constitute an anxiety disorder.
Clinical assessment considers symptom intensity, duration, functional impairment, and the broader context.
For individuals with an established anxiety disorder, preconception planning may provide an opportunity to evaluate current treatment and establish additional support.
6. Obsessive-Compulsive Disorder During Pregnancy and Postpartum
Obsessive-compulsive disorder involves unwanted intrusive thoughts, images, or urges and, in many cases, compulsive behaviors intended to reduce distress.
Perinatal OCD may involve intrusive thoughts about accidental or intentional harm involving an infant.
These experiences can be highly distressing.
An important clinical distinction exists between unwanted, ego-dystonic intrusive thoughts—thoughts experienced as inconsistent with a person's values—and psychotic beliefs or intentions involving harm.
Intrusive thoughts alone do not establish that someone intends to act on them.
However, appropriate clinical assessment is necessary to distinguish different presentations and evaluate safety.
Evidence-based treatment may include exposure and response prevention, a specialized form of cognitive behavioral therapy, and medication when appropriate.
Individuals experiencing these symptoms should have access to clinicians familiar with perinatal mental health.
7. PTSD and Previous Reproductive Trauma
Posttraumatic stress disorder can develop following exposure to traumatic events.
For some individuals, previous childbirth experiences may contribute to trauma-related symptoms.
Examples might include a medically complicated delivery, emergency intervention, severe hemorrhage, or pregnancy loss.
However, the severity of psychological distress does not necessarily correspond to how an event appears in a medical record.
One patient may experience an emergency cesarean delivery without persistent psychological symptoms.
Another may experience lasting distress following a delivery that clinicians considered medically uncomplicated.
Preconception counseling should therefore ask about the patient's experience rather than assume how a previous event affected them.
When PTSD is present, evidence-based psychological treatment and trauma-informed obstetric planning may be valuable.
The objective is to support the patient's psychological health and sense of agency during future reproductive care.
8. Screening for Depression and Anxiety Before Pregnancy
In 2023, the American College of Obstetricians and Gynecologists published Clinical Practice Guideline No. 4, Screening and Diagnosis of Mental Health Conditions During Pregnancy and Postpartum.
The guideline recommends screening individuals receiving well-woman, prepregnancy, prenatal, and postpartum care for depression and anxiety using standardized, validated instruments.
Screening should also occur during pregnancy and after childbirth.
However, a screening questionnaire is not equivalent to a psychiatric diagnosis.
A positive result indicates that additional clinical evaluation may be appropriate.
Screening should be connected to systems that provide timely assessment, treatment, and follow-up.
Simply administering a questionnaire without establishing access to appropriate care is insufficient.
9. What Mental Health Screening Tools Are Available?
Several validated instruments are commonly used in clinical practice.
The Patient Health Questionnaire-9, or PHQ-9, assesses symptoms associated with depression.
The Generalized Anxiety Disorder-7 questionnaire, or GAD-7, evaluates anxiety symptoms.
The Edinburgh Postnatal Depression Scale, or EPDS, is widely used in perinatal mental health screening.
Other instruments may help identify possible bipolar disorder, trauma-related symptoms, or additional concerns.
However, these tools have limitations.
Symptoms such as fatigue, sleep disturbance, or appetite changes can occur during pregnancy for reasons unrelated to psychiatric illness.
Scores also require interpretation according to the patient's history and circumstances.
Moreover, questionnaires do not reliably identify every condition.
The clinical interview remains essential.
10. Why Bipolar Disorder Screening Matters Before Antidepressant Treatment
One particularly important recommendation from ACOG is to screen for bipolar disorder before initiating medication for depression or anxiety when bipolar disorder has not already been assessed.
This matters because bipolar disorder can include depressive episodes that resemble unipolar depression.
However, treatment considerations differ.
Some antidepressants may contribute to mood destabilization in susceptible individuals, particularly when used without appropriate mood-stabilizing treatment.
Consequently, a history of depression should not automatically lead to the assumption that the person has unipolar major depressive disorder.
Relevant questions may address previous episodes of elevated or irritable mood, reduced need for sleep, increased energy, impulsivity, or other symptoms suggestive of hypomania or mania.
A positive bipolar screening result requires qualified psychiatric assessment.
It is not sufficient to establish the diagnosis independently.
11. Bipolar Disorder: Why Pregnancy Planning Matters
Bipolar disorder is a recurrent mood disorder involving episodes of depression, mania, hypomania, or combinations of mood symptoms.
The condition can affect energy, sleep, judgment, behavior, and functioning.
Some individuals experience prolonged periods of stability.
Others have frequent or severe episodes.
Pregnancy planning can be particularly important because discontinuing effective treatment may increase the risk of relapse.
The original 2008 AJOG article described studies in which mood episode recurrence was substantially more common among women who discontinued maintenance treatment.
The authors emphasized reviewing illness history, previous medication response, and relapse patterns before conception.
These principles remain relevant.
However, contemporary treatment decisions must also incorporate newer evidence concerning medication safety.
12. What Happens When Mood-Stabilizing Treatment Is Discontinued?
Discontinuation of maintenance treatment may increase relapse risk for some patients with bipolar disorder.
The magnitude of this risk varies.
Factors include illness severity, previous episode frequency, duration of stability, medication response, and the circumstances of discontinuation.
Abrupt discontinuation may be particularly problematic.
However, not every patient requires the same medication strategy.
Some individuals may have compelling reasons to consider changing treatment before conception.
Others may be best served by continuing an effective regimen.
The appropriate decision requires individualized psychiatric evaluation.
Pregnancy should not automatically trigger discontinuation of psychiatric medication, particularly when the medication is maintaining stability in a serious recurrent illness.
13. Lithium and Reproductive Mental Health
Lithium is an effective medication for bipolar disorder and has an established role in relapse prevention.
However, treatment during pregnancy requires careful assessment.
Lithium exposure has been associated with increased risk of certain congenital cardiac abnormalities, although absolute risks are substantially lower than some older estimates suggested.
Medication levels may also change during pregnancy because of changes in renal function and fluid balance.
Monitoring may therefore be necessary.
For some individuals, the benefits of continuing lithium may outweigh the risks.
For others, an alternative treatment may be appropriate.
The decision should involve a psychiatrist and obstetric clinician familiar with perinatal medication management.
Patients should not independently discontinue lithium because pregnancy is being considered.
14. A Newer Meta-Analysis on Lithium and Postpartum Relapse
A 2026 systematic review and meta-analysis examined lithium's role in preventing postpartum recurrence among women with bipolar disorder.
The investigators identified eight studies involving 554 women that contributed information about prophylactic lithium use.
The pooled postpartum recurrence proportion was approximately 21% among women receiving lithium compared with approximately 41% among those not receiving lithium.
These findings support lithium's potential value in relapse prevention.
However, interpretation requires caution.
The evidence came primarily from nonrandomized studies.
Differences in illness severity, treatment selection, and other factors could influence the results.
The analysis does not establish that lithium is the best medication for every patient.
Instead, it reinforces the importance of developing individualized postpartum relapse-prevention plans for individuals with bipolar disorder.
15. Valproate and Other Mood Stabilizers
Certain medications used to treat bipolar disorder have substantial reproductive safety considerations.
Valproate is particularly important.
Prenatal exposure is associated with increased risks of major congenital malformations and adverse neurodevelopmental outcomes.
Consequently, professional guidance generally recommends avoiding valproate during pregnancy when clinically feasible.
However, treatment changes must be managed carefully.
Some individuals have complex psychiatric histories, and abrupt discontinuation may produce serious consequences.
Other medications, including lamotrigine and selected antipsychotics, may be considered according to the patient's diagnosis and clinical response.
No medication is universally appropriate.
The objective is to establish an effective treatment plan that accounts for both psychiatric stability and reproductive risk.
16. Depression Treatment: Psychotherapy, Medication, and Individualized Care
Depression can be treated through several evidence-based approaches.
Psychotherapy is one option.
For some patients, structured interventions such as cognitive behavioral therapy or interpersonal psychotherapy may provide substantial benefit.
Medication may also be appropriate, particularly when symptoms are moderate to severe, recurrent, or significantly impair functioning.
Some individuals benefit from combined treatment.
The original AJOG paper emphasized that treatment decisions should reflect severity and illness history.
Current ACOG guidance continues to support individualized management.
It also recommends against withholding or discontinuing medications solely because of pregnancy or lactation.
The most appropriate treatment depends on clinical diagnosis, previous response, current symptoms, patient preferences, and reproductive considerations.
17. What Does Research Show About Antidepressant Discontinuation?
A 2022 population-based study examined antidepressant discontinuation before or during pregnancy and the risk of psychiatric emergency in Denmark.
Researchers compared women who discontinued antidepressants with matched women who continued treatment.
Discontinuation during pregnancy was associated with a higher risk of psychiatric emergency.
The estimated hazard ratio was 1.25.
However, discontinuation before pregnancy was not associated with a statistically significant increase in psychiatric emergencies in the studied cohort.
These findings suggest that timing and clinical circumstances may matter.
Nevertheless, the study was observational.
Reasons for discontinuation, illness severity, and other unmeasured factors may have influenced results.
The findings do not mean that every patient who stops antidepressant treatment will experience relapse.
They do support the importance of making treatment changes deliberately, with appropriate monitoring and follow-up.
18. Antidepressants and Fetal Development: Separating Risk From Confounding
Research concerning antidepressant exposure during pregnancy has examined congenital anomalies, preterm birth, neonatal adaptation, and neurodevelopmental outcomes.
However, interpretation is complicated by confounding by indication.
This occurs when the underlying condition being treated influences the outcome being studied.
For example, a woman taking an antidepressant may differ from an untreated woman in illness severity, other medical conditions, or relevant lifestyle factors.
Comparing their pregnancy outcomes without adequately accounting for these differences can produce misleading associations.
Some studies use sibling comparisons or other designs to address certain confounding factors.
However, no observational method eliminates all uncertainty.
Consequently, treatment decisions should consider drug-specific data rather than assume that all antidepressants have identical reproductive effects.
19. Neonatal Adaptation After Antidepressant Exposure
Some newborns exposed to certain antidepressants during late pregnancy experience transient symptoms after birth.
These may include changes in feeding, sleep, muscle tone, respiratory function, or irritability.
The term poor neonatal adaptation syndrome is sometimes used to describe these findings.
However, symptoms vary in severity and are often self-limited.
Other neonatal conditions may produce similar signs.
The possibility of neonatal adaptation should be considered during medication counseling.
However, it does not automatically establish that medication should be discontinued before delivery.
For some patients, discontinuation may increase maternal relapse risk without clearly preventing neonatal symptoms.
Decisions should be individualized and coordinated with the obstetric and psychiatric teams.
20. Emerging Evidence for Psychological Prevention
Psychotherapy may provide benefits beyond treatment of established depression.
A 2024 randomized clinical trial published in Nature Medicine evaluated an anxiety-focused cognitive behavioral intervention delivered during pregnancy in Pakistan.
The study included pregnant women with at least mild anxiety who did not have clinical depression at enrollment.
Participants received either the structured intervention or enhanced usual care.
The intervention involved six individual sessions delivered by trained non-specialist providers.
At six weeks postpartum, the intervention group had substantially lower odds of major depression or moderate-to-severe anxiety.
The adjusted odds ratio for the combined outcome was 0.19.
This corresponds to approximately 81% lower odds in the intervention group.
However, the findings should be interpreted within the study population and care setting.
They do not establish that every pregnant woman requires the same intervention.
Nor do they demonstrate that psychotherapy can replace medication for severe psychiatric illness.
Nevertheless, the study provides important evidence that structured psychological interventions can improve maternal mental health outcomes.
21. The Importance of Sleep in Perinatal Mental Health
Sleep is an essential component of psychological and physiological functioning.
Sleep disruption can influence attention, emotional regulation, metabolic processes, and subjective stress.
During pregnancy, sleep may be affected by discomfort, hormonal changes, breathing-related disorders, or other factors.
After childbirth, infant-care demands can produce substantial sleep fragmentation.
For individuals with certain psychiatric conditions, particularly bipolar disorder, sleep disruption may be clinically significant.
Irregular sleep patterns can coincide with mood destabilization in susceptible patients.
Consequently, preconception planning may include discussion of sleep health and strategies for managing postpartum sleep disruption.
However, sleep interventions should be realistic.
New parents cannot necessarily maintain uninterrupted sleep.
The objective is to create appropriate support and protect meaningful opportunities for rest where possible.
22. Postpartum Depression: Why Planning Should Begin Before Delivery
Postpartum depression can emerge after childbirth and may substantially affect psychological well-being and daily functioning.
Symptoms may include persistent sadness, loss of interest, fatigue, guilt, anxiety, or difficulty engaging in ordinary activities.
However, postpartum depression is not simply a predictable consequence of insufficient sleep or adjusting to parenthood.
It is a clinical condition requiring appropriate assessment.
A history of depression, previous postpartum depression, and other factors may influence risk.
Preconception care can therefore include discussion of previous episodes, current treatment, and available support.
An individualized postpartum plan may identify who will monitor symptoms, which clinicians will provide care, and how treatment will be accessed if necessary.
The objective is to reduce delays in recognizing and treating clinically meaningful symptoms.
23. Advances in Postpartum Depression Treatment
The treatment landscape for postpartum depression has evolved substantially since 2008.
In August 2023, the FDA approved zuranolone, the first oral medication specifically indicated for postpartum depression in adults.
Zuranolone is a neuroactive steroid that modulates GABA-A receptor activity.
The approved treatment is administered over 14 days.
Clinical studies demonstrated improvements in depressive symptoms compared with placebo.
However, the medication carries important safety considerations.
Its prescribing information includes a boxed warning concerning impaired driving ability and other potentially hazardous activities.
Patients are instructed not to drive for at least 12 hours after taking each dose during the treatment course.
The medication also requires consideration of sedation, drug interactions, reproductive precautions, and other clinical factors.
Zuranolone is a treatment for postpartum depression, not a routine preconception intervention.
Its approval nevertheless illustrates the increasing recognition of perinatal psychiatric illness as a field deserving targeted research and treatment.
24. Postpartum Psychosis: A Psychiatric Emergency
Postpartum psychosis is a severe psychiatric condition that may involve delusions, hallucinations, marked confusion, mania, or profound changes in behavior.
It frequently emerges during the early postpartum period.
Individuals with bipolar disorder or a history of postpartum psychosis may have increased risk.
However, postpartum psychosis can also occur without a previously recognized psychiatric diagnosis.
This condition requires immediate medical and psychiatric evaluation.
It should not be confused with postpartum depression or ordinary intrusive thoughts.
When symptoms involve impaired reality testing, severe disorganization, or risk of harm, urgent intervention is necessary.
Preconception planning is particularly important for individuals with a history of postpartum psychosis.
Their care may involve specialist medication planning, relapse prevention, and arrangements for rapid postpartum assessment.
25. Schizophrenia and Pregnancy Planning
Schizophrenia is a psychiatric disorder that may involve disturbances in perception, thinking, motivation, and functioning.
Its clinical presentation varies substantially.
Some individuals experience prolonged periods of stability with effective treatment.
Others require more intensive ongoing support.
The original AJOG paper emphasized that discontinuing antipsychotic medication could increase the risk of relapse and interfere with appropriate prenatal care.
Contemporary care continues to recognize the importance of maintaining psychiatric stability.
However, it is essential to avoid stigmatizing assumptions.
A diagnosis of schizophrenia does not automatically mean that someone lacks decision-making capacity or cannot become a capable parent.
Assessment should focus on the individual's actual symptoms, functioning, support needs, and treatment response.
26. Antipsychotic Medications and Metabolic Health
Antipsychotic medications can be essential for treating schizophrenia, bipolar disorder, and other psychiatric conditions.
However, some medications are associated with metabolic effects.
These may include weight gain, impaired glucose regulation, and changes in lipid metabolism.
Such effects can be relevant to preconception health.
For example, a patient receiving antipsychotic treatment may benefit from appropriate monitoring of weight, blood pressure, and glucose metabolism.
However, the metabolic effects of different medications vary.
Switching treatment solely because of weight concerns may not be appropriate if psychiatric stability is at risk.
A coordinated approach should consider both mental health and cardiometabolic health.
The goal is to manage relevant risks without compromising effective psychiatric treatment.
27. Stress, Cortisol, and the Limitations of Hormone-Based Explanations
Psychological stress is often discussed in relation to cortisol and the hypothalamic–pituitary–adrenal axis.
These systems are important in physiological adaptation.
However, the relationship between psychological experience and endocrine activity is complex.
Cortisol concentrations vary according to time of day, sleep, physical activity, illness, medications, and other factors.
A single cortisol measurement does not provide a comprehensive assessment of psychological stress.
Similarly, a commercial hormone profile cannot diagnose depression, anxiety, bipolar disorder, or schizophrenia.
Some endocrine conditions can produce psychiatric symptoms and may require medical evaluation.
However, this does not mean that most psychiatric illness results from a correctable hormone imbalance.
Preconception mental health assessment should prioritize validated diagnostic methods and appropriately selected medical investigations.
28. Can Nutrition and Exercise Support Maternal Mental Health?
Nutrition and physical activity can contribute to broader psychological and physical well-being.
Adequate nutritional intake supports essential physiological functions.
Regular movement can improve physical fitness and may reduce depressive or anxiety symptoms in some individuals.
Sleep and social connection also influence psychological health.
However, these interventions should not be presented as universal replacements for psychiatric treatment.
A patient with severe depression, bipolar disorder, or schizophrenia may require medication and specialist care.
Lifestyle interventions may serve as complementary supports when appropriate.
Their effectiveness also depends on access, feasibility, physical health, and patient preferences.
The most useful strategy is to incorporate sustainable health behaviors into a clinically appropriate treatment plan.
29. Relationships, Social Support, and Psychological Readiness
Pregnancy and parenthood involve changes in relationships and responsibilities.
The original AJOG article emphasized the importance of social support.
This remains relevant.
Support may involve emotional connection, practical assistance, financial resources, transportation, childcare, or help accessing healthcare.
However, social support is not synonymous with being married or having a particular family structure.
Different individuals rely on different networks.
The quality and reliability of support may matter more than whether a network matches a conventional ideal.
Preconception counseling can help prospective parents identify available resources and potential gaps.
For individuals with recurrent psychiatric illness, a trusted support person may participate in relapse-prevention planning when the patient wishes.
However, confidentiality and personal autonomy must remain central.
30. Reproductive Autonomy and Psychiatric Conditions
A psychiatric diagnosis does not automatically eliminate a person's ability to make reproductive decisions.
Nor should a history of depression, anxiety, bipolar disorder, or schizophrenia be treated as a reason to discourage pregnancy without individualized evaluation.
Patients deserve accurate information about possible risks, available treatments, and reproductive options.
Some may decide to pursue pregnancy while continuing psychiatric medication.
Others may prefer to delay conception until symptoms are more stable.
Still others may choose not to have children.
These are personal decisions.
The role of the healthcare team is to provide appropriate information, support informed consent, and help individuals access suitable treatment.
Mental health care should promote autonomy rather than undermine it.
31. A Comprehensive Preconception Mental Health Assessment
An evidence-informed assessment may include several important domains.
Psychiatric history: Previous diagnoses, episodes, hospitalizations, and current symptoms.
Treatment history: Medications, psychotherapy, previous response, and adverse effects.
Relapse patterns: Circumstances associated with previous episodes or symptom exacerbations.
Pregnancy history: Previous perinatal depression, mania, psychosis, or trauma-related symptoms.
Current functioning: Sleep, daily activities, relationships, and other relevant indicators.
Medical conditions: Thyroid disease, anemia, metabolic disorders, or other conditions when clinically indicated.
Substance use: Tobacco, alcohol, cannabis, and other exposures relevant to health.
Social support: Practical resources, trusted relationships, and anticipated postpartum assistance.
Medication planning: Reproductive safety, illness stability, and specialist coordination.
Postpartum preparation: Monitoring, follow-up arrangements, and an individualized relapse-prevention strategy.
Not every individual requires every component.
Assessment should be proportionate to clinical needs.
32. Practical Steps for Prospective Parents
A comprehensive preparation strategy can include the following priorities.
Discuss previous or current psychiatric conditions with an appropriately qualified clinician before attempting pregnancy.
Obtain appropriate screening for depression, anxiety, and bipolar disorder when indicated.
Review psychiatric medications with the prescribing professional rather than stopping treatment independently.
Consider evidence-based psychotherapy when appropriate for the diagnosis and symptom severity.
Address persistent sleep disturbance and other relevant health concerns.
Review substance use and obtain appropriate support when necessary.
Identify practical resources for pregnancy and postpartum care.
Develop a relapse-prevention plan when there is a history of recurrent or severe psychiatric illness.
Establish access to psychiatric and obstetric follow-up during pregnancy and after childbirth.
Seek urgent professional assessment when symptoms involve psychosis, mania, or suicidal thoughts.
The objective is not to eliminate every possible psychological stressor before conception.
It is to establish appropriate care and support for the individual's mental health needs.
33. How This Research Informs Our Preconception Care
We recognize that psychological well-being is an important component of comprehensive reproductive health.
Within our conscious conception, women's wellness, Functional Psychology, and Stress Well services, we emphasize understanding the interactions among lived experience, health behaviors, physiological demands, and the social environment.
Preconception wellness may involve supporting sleep habits, nutrition, movement, stress-management skills, and access to appropriate psychological resources.
However, we recognize that psychiatric disorders require clinically appropriate diagnosis and treatment.
Depression is not simply a consequence of inadequate stress management.
Bipolar disorder is not a generalized hormonal imbalance.
And schizophrenia cannot be addressed through lifestyle changes alone.
For individuals with established psychiatric conditions, management should involve appropriately qualified mental health professionals.
Prescription medication decisions must remain with the relevant prescribing clinicians.
Our role is to support health education, identify meaningful wellness needs, and facilitate collaborative care.
We also recognize the limitations of emerging research concerning inflammation, neuroendocrine signaling, microbiome biology, and psychiatric health.
These scientific relationships deserve study.
However, they should not be used to justify unvalidated testing or replace established psychiatric care.
The goal is to support the whole person without confusing comprehensive wellness with a substitute for specialized mental healthcare.
Conclusion: Mental Health Is an Essential Part of Reproductive Preparation
Preparing for pregnancy involves more than reproductive anatomy, nutritional status, and laboratory measurements.
It also involves psychological health.
For individuals with depression, anxiety, bipolar disorder, schizophrenia, or other psychiatric conditions, preconception care offers an opportunity to evaluate treatment, establish support, and prepare for the demands of pregnancy and parenthood.
The original 2008 AJOG article recognized the importance of psychiatric screening and individualized treatment planning.
Since then, newer guidelines have strengthened the case for integrating mental health into routine reproductive healthcare.
Research has clarified the risks associated with discontinuing effective treatment in certain circumstances.
Structured psychological interventions have demonstrated meaningful benefits for selected patients.
And advances in pharmacology have expanded the options available for treating postpartum depression.
However, the science also reinforces the importance of individualized judgment.
Not every psychiatric condition follows the same course.
Not every medication carries the same reproductive risks.
And psychological distress cannot be reduced to one hormone, neurotransmitter, or inflammatory pathway.
The objective of preconception mental healthcare is not to ensure that prospective parents never experience stress, anxiety, or emotional difficulty. It is to identify meaningful mental health needs, maintain appropriate treatment, and support psychological well-being before, during, and after pregnancy.
We believe comprehensive reproductive preparation should recognize physical, psychological, biological, and social health as interconnected dimensions of the human experience.
Because preparing for pregnancy also means caring for the mental health and well-being of the person who will experience it.
Research References
Frieder A, Dunlop AL, Culpepper L, Bernstein PS. The clinical content of preconception care: women with psychiatric conditions. American Journal of Obstetrics and Gynecology. 2008;199(6 Suppl 2)–S332. https://doi.org/10.1016/j.ajog.2008.09.001
American College of Obstetricians and Gynecologists. Screening and diagnosis of mental health conditions during pregnancy and postpartum. Clinical Practice Guideline No. 4. Obstetrics & Gynecology. 2023;141:1232–1261. https://doi.org/10.1097/AOG.0000000000005200
American College of Obstetricians and Gynecologists. Treatment and management of mental health conditions during pregnancy and postpartum. Clinical Practice Guideline No. 5. Obstetrics & Gynecology. 2023;141:1262–1288. https://doi.org/10.1097/AOG.0000000000005202
Surkan PJ, Malik A, Perin J, et al. Anxiety-focused cognitive behavioral therapy delivered by non-specialists to prevent postnatal depression: a randomized, phase 3 trial. Nature Medicine. 2024;30:675–682. https://doi.org/10.1038/s41591-024-02809-x
Liu X, Agerbo E, Li J, et al. Antidepressant discontinuation before or during pregnancy and risk of psychiatric emergency in Denmark: a population-based propensity score-matched cohort study. PLOS Medicine. 2022. https://pubmed.ncbi.nlm.nih.gov/35100270/
Sharma V, et al. Lithium in the prevention of postpartum recurrence of mood disorders: a systematic review and meta-analysis. 2026. https://pubmed.ncbi.nlm.nih.gov/42949427/
U.S. Food and Drug Administration. FDA approves first oral treatment for postpartum depression. August 4, 2023. https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-treatment-postpartum-depression
U.S. National Library of Medicine. ZURZUVAE (zuranolone): current prescribing information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f18e53b0-d0bb-422d-8de7-ab64b7292b29
American College of Obstetricians and Gynecologists. Patient screening: perinatal mental health. https://www.acog.org/programs/perinatal-mental-health/patient-screening
American College of Obstetricians and Gynecologists. Assessment and treatment of perinatal mental health conditions. https://www.acog.org/programs/perinatal-mental-health/assessment-and-treatment-of-perinatal-mental-health-conditions
American College of Obstetricians and Gynecologists. Implementing perinatal mental health screening. https://www.acog.org/programs/perinatal-mental-health/implementing-perinatal-mental-health-screening